All PTGFRN reagents are produced in house and quality controlled, including 1 PTGFRN Antibody, 13 PTGFRN Gene, 1 PTGFRN Lysate, 1 PTGFRN Protein. All PTGFRN reagents are ready to use.
Recombinant PTGFRN proteins are expressed by HEK293 Cells with fusion tags as C-His.
PTGFRNantibodies are validated with different applications, which are WB.
PTGFRNcDNA clones are full length sequence confirmed and expression validated. There are 13 kinds of tags for each PTGFRN of different species, especially GFP tag, OFP tag, FLAG tag and so on. There are three kinds of vectors for choice, cloning vector, expression vector and lentivrial expression vector.
EWI-F, also known as PTGFRN, is inversely related to the loss of CD9. Its expression correlates with the metastatic status of hLT (n=55). EWI-F inhibits the binding of prostaglandin F2-alpha (PGF2-alpha) to its specific FP receptor, by decreasing the receptor number rather than the affinity constant. EWI-F expression positively correlates with the metastatic status of hLT, and that the upregulation of EWI-F expression could be one of the mechanisms underlying the loss of CD9 in solid tumours.